Valthos Buyer & Influence Persona Map

Compiled 2026-05-11. Companion to the market primer. Named individuals across federal (DoD + HHS + IC), policy/Hill, and commercial. [unverified] flags items not pinned to a primary source. Government roles, especially political appointees, churn , re-verify before outreach.

Table of Contents

1. Top 20 highest-leverage personas
2. Federal , DoD
3. Federal , HHS
4. Federal , IC
5. Executive Branch policy
6. Congressional , appropriators, authorizers, members of interest
7. Commissions, think tanks, industry associations
8. Commercial , AI labs
9. Commercial , DNA synthesis providers
10. Commercial , Pharma / large biotech
11. Commercial , CROs, cloud labs, Ginkgo
12. Commercial , insurance & reinsurance
13. Commercial , defense primes & FFRDCs
14. Commercial , agriculture, food, critical infra, hospitals, VC referral
15. Outreach sequencing & warm-intro paths
16. Sources of error & honest caveats

1. Top 20 highest-leverage personas

Ordered by combined "budget authority × accessibility × mission fit".

2. Federal: DoD

2.1 DTRA (Defense Threat Reduction Agency)

Why it matters: largest DoD chem-bio S&T customer outside DARPA. RD Directorate ~$1B/yr. FY25-2034 Chem-Bio Fundamental Research BAA (HDTRA1-25-S-0001) offers up to $1M/yr × 5 yrs per award, ~30 awards/yr.

Budget Holders

• Maj. Gen. Lyle K. Drew, USAF: Acting Director, DTRA. Top of ~$2.4B agency portfolio.
• Dr. Rhys M. Williams: Executive Director, DTRA (career SES / COO).
• Dr. James Petro, SES: Director, Research and Development (RD) Directorate. Most important DTRA budget holder for Valthos. Oversees ~$1B+/yr S&T portfolio.
• Ms. Teresa Kless, SES: Director, Acquisitions, Contracts and Logistics (AL).
• Dr. Robert Pope, SES: Director, Cooperative Threat Reduction (CT). Runs BTRP (Biological Threat Reduction Program). CTR ~$300-400M/yr.

Front-Door

• Dr. Robert Kristovich: JSTO Director (Chemical & Biological Technologies Department / Joint Science & Technology Office). Primary technical front door. [2024 DVIDS attribution; verify 2026 currency]
• Ms. Amanda L. Richardson, SES: RD leadership (verify current title , predecessor role to current Petro position).
• Mr. Ed Emmons: Mentor-Protégé / Small Business Program Manager, DTRA OSBP. Direct line: 571-616-4195, DTRA_OSBP@mail.mil. Actual industry front door for a seed-stage startup.
• DTRA OSBP outreach mailbox: dtra.belvoir.al.mbx.osbp-outreach-2@mail.mil, 703-767-3436.
• FY25-2034 BAA mailbox: dtra.belvoir.rd.mbx.rd-cb-frbaa25-34-a@mail.mil. Next white-paper deadline 2 March 2026 for Topics B1-B6.

End Users

• RDML Stephen "Josh" Jackson, USN: Acting Director, Operations and Integration (OI). Connects bio capability to COCOMs and FVEY partners.

2.2 CPE CBRND (formerly JPEO-CBRND, rebranded April 2026)

Why it matters: acquisition arm for DoD CBRN capabilities. FY26 CBDP request = $1.61B ($1.189B RDT&E + $421M procurement).

Budget Holders

• Mr. Darryl J. Colvin: Capability Program Executive (CPE) / Joint Program Executive Officer for CBRN Defense.
• Ms. Nicole Kilgore: Deputy CPE / Deputy JPEO. Previously JPM CBRN Medical Deputy , has deep MCM acquisition chops.

Front-Door , Joint Project Managers / Joint Project Leads

• COL John Nuckols: JPM CBRN Medical. Single most important MCM portfolio. Predecessor COL Ryan Eckmeier in legacy materials.
• Mr. Bruce Goodwin: JPL CBRND Enabling Biotechnologies (JPL EB). Mission-exact fit for Valthos. LinkedIn: linkedin.com/in/bruce-goodwin-b7b4455.
• Mr. Paul Gietka: JPL CBRN Integration (data/IT layer for joint CBRN).
• Mr. Steven Batts: JPM CBRN Protection.
• Mr. Timothy Tharp: JPM CBRN Sensors.
• Ms. Lindsay Longobardi: JPM CBRN Special Operations Forces. ⬆️ BUMPED PRIORITY (May 2026) after Valthos's first publicly announced FDE hire was an ex-Green Beret medic , strongly suggests SOF-medical is an anchor ICP. Faster, lower-friction acquisition path than conventional. Was Deputy JPL EB , knows the bio side. One of the most aligned single contacts in DoD for what Valthos is building.
• Ms. Nicky Dorsey: Acting Deputy JPL CBRND EB. Day-to-day deputy for Goodwin; often easier first contact.
• JPM CBRN Medical TechWatch: public-private partnership pathway specifically built to bring in companies like Valthos.

2.3 DARPA Biological Technologies Office (BTO)

Office Leadership

• Dr. Michael Koeris: BTO Office Director (since April 2024). PhD biomedical engineering (BU); ex-startup founder; biggest AI-bio evangelist inside DARPA. LinkedIn: linkedin.com/in/mkoeris.
• Robert Saperstein, PhD: supports the Office Director [unverified , Wikipedia secondary].

Active BTO Program Managers as of 2026 , pick by program fit:

• Dr. Tiffany Prest (Aug 2022). Infectious diseases, microbial ecology, ML-for-microbes. Programs: AMPHORA, Arcadia, EMBER.
• Dr. Michael Feasel (Aug 2022). Molecular tox, chem/bio detection. Programs: ABC, Hermes, Protean, RIDDL.
• Dr. Anne Cheever (Aug 2020). Biosecurity, bioengineering, bioinformatics. Email pattern: ice@darpa.mil. Highest-affinity BTO PM for Valthos's biodefense pitch.
• Lt. Col. Adam Willis, M.D. (Jul 2023). Combat casualty / critical care.
• Dr. Abhishek Singharoy (Jan 2024). Bio-attribution Challenge (2026 , directly relevant), NODES, Protean, SMS.
• Dr. Jeffrey Zaleski (Aug 2024). Bioinorganic. Program: ICE.
• Cmdr. Cody Ray Thornton, PhD: Deputy PM (Oct 2024). Acute public health, CBRN prep.
• Dr. Sushma Savarala (Nov 2024). Leads EQUIP-A-Pharma (agile pharma manufacturing).
• Col. (ret.) Jeremy Pamplin, M.D. (May 2025). Telemedicine, austere medicine.
• Dr. Roozbeh Jafari (Jul 2025). Digital health, wearables. Programs: BEST, BETR, VITAL.
• Dr. William Mounfield (Aug 2025). Chem-bio defense, flexible biomfg. Programs: WUD, Fleetwood, Cornucopia. Was BTO Sr S&T Advisor before becoming PM , knows the portfolio cold.
• Dr. Bethany Brown: Deputy PM (Apr 2026). Clinical science / transfusion.

Operational support (named): Daniella Superlano (contracts), Paola Whitlock, Ryann Glaccum, Katie Freeman, Lydia Richard (CMO).

Best contact paths: DARPA Forward, SynBioBeta, BTO Office-Wide BAA (HR001120S0019 series), DARPA Connect events ("Biological Breakthroughs: Meet DARPA's BTO").

2.4 DIU (Defense Innovation Unit)

• Mr. Owen West: Director, DIU (assumed role March 2026, succeeding Acting Director Emil Michael). New priorities: 3-year fielding, "combat power."
• Dr. Christian Whitchurch: Director, Human Systems Portfolio. Based Mountain View. Single most important DIU contact for Valthos. Ex-DTRA Chief Scientist for Detection & Diagnostics.
• DIU CSO inbox: HQ0845-20-S-C001 standing CSO mechanism. Areas of Interest on diu.mil/work-with-us.
• March 2025 biosurveillance award POC: RDML Brandon Taylor, DHA Public Health Director (quoted on the AI-driven biosurveillance prototype announcement).

2.5 USAMRIID / USAMRDC / CDMRP (Fort Detrick)

Budget Holders

• Maj. Gen. Paula C. Lodi: Commanding General USAMRDC; Director R&D, DHA; Senior Commander Fort Detrick. Three-hat budget owner.
• COL Mark G. Hartell: Director, CDMRP. Manages $1.27B FY26 across 34 programs. Military Deputy: LTC Tanekkia Taylor-Clark.

Front-Door / End Users

• COL Tracy J. Ostrom: Commander, USAMRIID (took command spring 2025).
• SGM Emily L. Green: Senior Enlisted Leader, USAMRIID.
• Dr. Joel Bozue: Chief, Molecular Pathogenesis Branch, Bacteriology Division.
• Dr. Christopher Cote: Deputy Chief, Bacteriology Division.
• Dr. Christopher Stefan: Chief, Developmental Diagnostics Branch, Diagnostic Systems Division.
• Lt. Col. M. Kelly Hourihan: Director, Special Pathogens Clinical Diagnostic Lab.
• Capt. C. Ian Davis: Deputy Chief, Applied Diagnostics Branch. Ran field sequencing at African Lion 2025. ⬆️ BUMPED PRIORITY (May 2026): Davis is the closest single USAMRIID contact running field-deployable pathogen sequencing , the exact product axis Valthos's FDE hire signals. Direct technical peer for any field-edge demo or pilot.
• Public affairs contact: Caree Vander Linden, teresa.l.vanderlinden.civ@health.mil.

2.6 OSD level

• Dr. Robert Kadlec: ASD ND-CBD (Asst Sec of Defense for Nuclear Deterrence, Chemical & Biological Defense Policy and Programs), confirmed Dec 29, 2025. Single highest Senate-confirmed bio authority in DoD. Top priority outreach.
• Mr. Ian Watson: DASD CBRND (CBDP planning/programming, $1.61B FY26).
• OUSD R&E bio principal director [unverified for 2026].

2.7 Service-level innovation (lower priority for Valthos)

• AFWERX bio: route via afwerx.com/contact + IGNITE portal. Lower priority.
• SOFWERX: Anthony "Tony" Pettengill (Deputy Director), Dennis Hocking (PM). Runs "Vulcan SOF" CBRN tech-watch events. ⬆️ BUMPED PRIORITY (May 2026): given Valthos's FDE hire is ex-Green Beret + the explicit "austere environments" product framing, SOFWERX is now a near-top federal channel. Direct path: submit a Tech Tuesday Scout Card on the Vulcan platform; 20-min Tech Tuesday briefing slot to all-government audience. CBRN-focused SOCOM exercises (e.g., Dragon Spear) source from this pipeline.
• ONR Code 34: Dr. Thomas McKenna (Code 341, thomas.m.mckenna4.civ@us.navy.mil); LCDR Geoffrey Ciarlone, PhD (Code 342, geoffrey.e.ciarlone.mil@us.navy.mil).

3. Federal: HHS

3.1 BARDA (Biomedical Advanced Research and Development Authority)

Budget Holders

• Gary L. Disbrow, Ph.D.: Director, BARDA / Deputy Assistant Secretary, ASPR. Controls $2.1B/yr ($970M ARD + $820M BioShield SRF + ~$300M Pan Flu).
• Robert Johnson, Ph.D.: MCM Programs Director (BARDA #2 program lead). Operational owner of platform-tech bets including AI.
• Linda Lambert, Ph.D.: Deputy Director, BARDA / Director, MCM Program Support Services [verify currency].

Front-Door

• Joffrey Benford, MBA: Director, Division of Contract Management & Acquisitions (CMA) / Deputy Head of Contracting Activity, ASPR. Every BARDA contract closes through his shop. LinkedIn: linkedin.com/in/joffreybenford.
• Enrique Mañán: CMA Chief of Staff and Acting Associate Director of Contracts Operations.
• Ashim Subedee, Ph.D.: Acting Director, DRIVe + Director, DRIVe Catalyst Office. Runs EZ-BAA, BARDA Ventures, Accelerator Network. LinkedIn: linkedin.com/in/asubedee.
• TechWatch entry: TechWatchInbox@hhs.gov. Quad-chart funnel, ~30-day review.
• John Tegeris, Ph.D.: PM, BARDA TechWatch.

End Users , Division Directors (pick by product fit)

• Christopher Houchens, Ph.D.: Director, Division of CBRN Medical Countermeasures. Highest-fit BARDA division for Valthos. Owns Project BioShield procurements. LinkedIn: linkedin.com/in/chris-houchens-6b13832.
• Kimberly Armstrong, Ph.D., MT(ASCP): Director, Influenza & Emerging Infectious Diseases Division (IEID). Owns Project NextGen.
• Rodney Wallace: Director, Detection, Diagnostics & Devices Infrastructure (DDDI).
• April Brys, Ph.D.: Director, Non-Clinical Development (DNCD). Animal Rule pathway bridge.
• Michael Angelastro: Director, Pharmaceutical Countermeasures Infrastructure (PCI).
• Bill G. Kapogiannis, M.D., FIDSA: Director, Clinical Development Division (DCD).

3.2 ASPR (Administration for Strategic Preparedness and Response)

Status flag: Assistant Secretary VACANT since Jan 20, 2025 (Dawn O'Connell departed); no Senate-confirmed successor as of May 2026.

• Nikki Bratcher-Bowman: Principal Deputy Assistant Secretary & COO, ASPR. Effective operational head when ASPR vacant. Career SES.
• Arlene Joyner, MS, PMP: DAS & Director, Center for Industrial Base Management and Supply Chain. Owner of advanced manufacturing, PPE, supply chain.
• Brian Mazanec, Ph.D.: DAS, Center for HHS Coordination Operations & Response Element (H-CORE) / Acting DAS Center for Preparedness.
• Jonathan N. Greene: DAS, Center for Response. Operational deployment + NDMS.
• Steve Adams, MPH: DAS & Director, Strategic National Stockpile (SNS). Holds procurement pen on MCM replenishment (~13 MCM transitions FY23–27, ~$5.3B replenishment runway).
• Lisa Dillard: Deputy Director, SNS.

3.3 ARPA-H

Status: FY26 appropriation $1.5B (Congress rejected proposed $945M cut).

• Alicia Jackson, Ph.D.: Director (sworn in Oct/Nov 2025). Former DARPA BTO Deputy. Founder of Evernow. Keynoted JPM 2026.
• Tyler Best: Acting Director (also Deputy Director), Health Science Futures (HSF). LinkedIn: linkedin.com/in/tylerbest. Now the senior HSF champion to brief (Kilianski departed ~May 2026). Approach with Solution Summary aimed at biothreat/MCM-adaptation thrust.
• Andy Kilianski, Ph.D.: DEPARTED ARPA-H ~May 2026. Now Chief Science & Technology Officer, UCSF Quantitative Biosciences Institute (QBI). Leading translation and product development across infectious disease, cancer, neuroscience research. Strategic implications: (1) QBI specializes in protein-protein interaction (PPI) maps , natural STTR / R01 co-PI fit for Valthos's PLM stack; (2) Kilianski is SF-based, same as Valthos's DARPA grant PoP; (3) he is publicly recruiting new ARPA-H PMs ("I'd be happy to talk to anyone about the PM role at ARPA-H and how to build within the USG"). high-leverage opportunity to source a sympathetic PM. ARPA-H jobs are term-limited by design. LinkedIn: linkedin.com/in/andy-kilianski-a0116544.
• Acting Deputy Director, HSF (biothreat/MCM PM seat): [VACANT / new appointee post-Kilianski; verify via arpa-h.gov/about/people]. Identifying and engaging the successor is the #1 ARPA-H priority for Valthos's first 30 days.
• Glen Coppersmith: Acting Director, Proactive Health.
• Natalie Kates: Acting Director, Scalable Solutions. Former CTO White House COVID-19 Response.
• Gina Kost: Deputy Director, Resilient Systems (PARADIGM program).
• Etaf Khan: Assistant Director, Resilient Systems (ex-CBO, ex-OSD).
• Sabrina Stronsky: Assistant Director, Program Management, Scalable Solutions. Prior bench scientist at BSL-3/4.
• PMs (biothreat/MCM-adjacent):
  • Dr. Jessica Green (Resilient Systems). healthy building / airborne pathogen monitoring expert; ex-Phylagen CTO/CEO.
  • HSF PMs: Daria Fedyukina, Ileana Hancu, Shannon Greene, Jean Hebert, Wilfred Ngwa, Calvin Roberts.
  • Resilient Systems PMs: Andrew Carney, Bradley Karlin, Mansoor Khan, Erika Kim, Bon Ku, Yoram Vodovotz.
  • Scalable Solutions PMs: Kate Arnold, Gloria Elliott, Larissa May, John Schiel, Haider Warraich, Pierre Mourad.

3.4 NIH / NIAID

• NIAID Director: VACANT/ACTING (Jeanne Marrazzo departed for IDSA CEO effective Jan 12, 2026). Acting director currently under NIH Director Bhattacharya.
• NIH Director: Jay Bhattacharya , concurrently performing CDC delegable duties. ~$50B NIH authority.
• George Kennedy: Director, NIAID Office of Acquisitions. Deputy: Dante Stumpo. Sheila Barber , Health Science Administrator.
• Emily Erbelding, M.D., M.P.H.: Director, DMID (Division of Microbiology and Infectious Diseases). Owner of NIAID's biodefense + EID extramural portfolio. Direct line for Omnibus BAA proposals.

3.5 CDC

Status: Director Monarez fired Aug 2025; Bhattacharya acting since Feb 2026; Erica Schwartz nominated April 16, 2026 (pending Senate confirmation).

• Henry Walke, M.D., M.P.H.: Director, Office of Readiness & Response (ORR). Owns CDC's preparedness / select-agent / response pipeline; led COVID response 2020-21.
• Ian Williams, Ph.D., M.S.: Deputy Director, ORR.
• Joanne Andreadis, Ph.D.: Associate Director, Office of Science and Lab Readiness, ORR.
• Joanna Prasher, Ph.D., M.P.H.: Associate Director, Cross Agency Preparedness, ORR.
• Christopher R. Braden, M.D.: Acting Director, NCEZID.
• Margaret (Peggy) Honein: Director, NCEZID DIDRI. Highest-fit NCEZID division for Valthos.
• Fernando Torres-Vélez: Director, Division of High-Consequence Pathogens and Pathology (DHCPP). Direct biothreat fit.
• Mike Bell: Director, Division of Healthcare Quality Promotion (DHQP).
• Chris Brown, Ph.D., M.P.H.: Director, Division of Emergency Operations (DEO).
• Lisa Barrios, DrPH, ScM: Director, Division of Readiness and Response Science.

3.6 FDA MCMi (Medical Countermeasures Initiative)

• Michael Mair: Director, Office of Regulatory and Emerging Science (ORES); coordinates FDA's MCMi. Long biosec career (JHU, UPMC Center for Biosecurity, ASPR policy). Best FDA contact for biodefense MCM developers.
• CDER Counter-Terrorism and Emergency Coordination Staff (CTECS):
  • Rosemary Roberts, M.D. , Director.
  • Brad Leissa, M.D. , CDER lead.
  • Andrea Gormley, Pharm.D., J.D. , Associate Director, Regulatory.
  • Kelly Ngan, Pharm.D., M.P.H. , Associate Director.
  • Susan McDermott, M.D. , MCM Development + Animal Model Qualification Program lead. Susan.McDermott@fda.hhs.gov. Critical for Animal Rule pathway.
• Mailbox: AskMCMi@fda.hhs.gov.

4. Federal: IC

4.1 IARPA

• Rick Muller, Ph.D.: Director, IARPA (6th full-time). Quantum/computing background; ex-Sandia, ex-DOE NSCI.
• Jack Cooper, Ph.D.: Office Director for Analysis (since Jan 2025).
• Michael Patterson, Ph.D.: PM. SINGLE MOST IMPORTANT IC CONTACT FOR VALTHOS. Owns TEI-REX (low-dose noninvasive biodosimetry) and the B24IC targeted seedling on countering traditional bio-threats. Advises four IC postdocs.
• Tom Schneider, Ph.D.: PM (joined Aug 2023). Co-PM on B24IC.

4.2 In-Q-Tel

Status: B.Next (IQT's bio team) publicly stated (Jessica Dymond, CNAS Feb 2025) that biotech startups are "dying on the vine" , IQT is actively shopping for biodefense-AI deals.

• CEO: Steve Bowsher [verify currency].
• Tara O'Toole, M.D., M.P.H.: EVP & Senior Fellow; Director of B.Next. Ex-DHS S&T Under Secretary; Dark Winter / Atlantic Storm co-author; ex-CEO UPMC Center for Biosecurity. The call for Valthos. LinkedIn: linkedin.com/in/tara-o-toole-6b2158127.
• Kevin O'Connell: SVP, Technical Co-Lead B.Next. At IQT since 2007; ex-Army Edgewood CBC. The operational deal-doer.
• Dr. Michelle Rozo: VP, Technical Capabilities; also Vice Chair of NSCEB. Cross-pollinates IQT + commission worlds. Ex-NSC Director of Tech & National Security; ex-OUSD R&E Principal Director for Biotech.
• Jessica Dymond: VP for Technology; publicly stated biotech-funding gap thesis (Feb 2025 CNAS).
• A.J. Bertone: Managing Partner; leads US investment activities (Army vet, ex-Bain).

4.3 NCMI (National Center for Medical Intelligence, within DIA)

• Lt. Gen. James H. Adams III, USMC: Director, DIA (25th director; assumed role Feb 20, 2026). NCMI staffing/funding flows through him.
• NCMI Director: [not publicly named; historically O-6 or SES with medical/intel background. Path: AFCEA Intelligence / AFMIC events; DIA Industry Day.]
• NCMI division chiefs cover (1) infectious disease, (2) environmental health, (3) global health systems, (4) medical S&T.

4.4 ODNI: National Counterproliferation and Biosecurity Center (NCBC)

• NCBC Director: [not publicly named for May 2026]. Appointed by DNI; reports to DNI.
• NCBC structure: Office of Advanced Capabilities + Office of Mission Integration.
• Biological Sciences Experts Group (BSEG): formal channel to outside academic/industry experts. Cleanest entry path for Valthos into NCBC.

5. Executive Branch policy

• Michael Kratsios: Director, OSTP. Authored "Winning the Race: America's AI Action Plan" (July 23, 2025) which contains the central AI×CBRN risk and biosecurity sections that frame Valthos's positioning. Co-chairs PCAST with David Sacks. Ex-Scale AI; ex-US CTO Trump I. LinkedIn: @mkratsios47.
• Dr. Gerald Parker: Director, WH Office of Pandemic Preparedness and Response Policy (OPPR) + NSC Senior Director for Biosecurity and Pandemic Response (since Feb 2025). Trump II "biodefense czar." Former USAMRIID commander, former HHS Principal Deputy ASPR. Texas A&M Bush School.
• Carrie D. Wolinetz, Ph.D.: Deputy Director, Health & Life Sciences, OSTP [unverified , confirm current incumbent]. Previously NIH Associate Director for Science Policy; stood up NExTRAC.
• OSTP biosecurity / dual-use policy lead [unverified named individual]. Ask Caitlin Frazer (NSCEB) or Jaime Yassif (NTI) for current name.
• OMB Program Associate Director, Health (PAD-H) [unverified named individual]. Owns biodefense passback for HHS-ASPR, DoD CBDP, DHS CWMD. Per NDAA Sec. 363 (FY21), OMB produces the consolidated biodefense budget annually.

6. Congressional: appropriators, authorizers, members of interest

6.1 Senate Appropriators

• Sen. Susan Collins (R-ME): Chair, Senate Approps full committee. Led FY26 reversal of proposed 40% NIH cut.
• Sen. Mitch McConnell (R-KY): Chair, SAC-Defense.
• Sen. Chris Coons (D-DE): Ranking, SAC-Defense. Biotech-friendly; Delaware ties.
• Robert Leonard: Clerk/Staff Director, SAC-D. Career SAC-D PSM since 2019; promoted clerk Aug 2024. LinkedIn: linkedin.com/in/robert-leonard-6143716. Drafts SAC-D bill text.
• Sen. Shelley Moore Capito (R-WV): Chair, SAC-LHHS. Writes BARDA/ARPA-H/NIH/CDC bill (FY26 sustained BARDA, BioShield, SNS, IBMSC).
• Sen. Tammy Baldwin (D-WI): Ranking, SAC-LHHS.

6.2 Senate Authorizers / Intel

• Sen. Roger Wicker (R-MS): Chair, SASC. Filed FY26 NDAA July 16, 2025 with biotech provisions (Biotechnology Management Office, $137M MILCON for NRL Biomolecular Sci & Synthetic Biology Lab).
• Rick Berger: Staff Director, SASC (effective Dec 2025). Previously SASC Budget Director since 2019.
• Sen. Jack Reed (D-RI): Ranking, SASC.
• Sen. Tom Cotton (R-AR): Chair, SSCI. Hawkish on China bio.
• Ryan Tully: Staff Director, SSCI.
• Sen. Mark Warner (D-VA): Ranking, SSCI. Drove FY25 IAA biotech provisions.

6.3 House Appropriators

• Rep. Ken Calvert (R-CA): Chair, HAC-Defense.
• Rep. Betty McCollum (D-MN): Ranking, HAC-Defense.
• HAC-LHHS: Chair Rep. Robert Aderholt (R-AL) [verify]; Ranking Rep. Rosa DeLauro (D-CT) , long-time biodefense champion (created BARDA in 2006).

6.4 House Authorizers / Intel

• Rep. Don Bacon (R-NE): Chair, HASC CITI Subcommittee. Jurisdiction over AI, cyber, emerging tech in DoD.
• Sarah Moxley: Professional Staff Member / Staff Lead, HASC CITI. Handles AI/quantum/IoT. LinkedIn: linkedin.com/in/sarah-moxley-26799b42.
• Rep. Ro Khanna (D-CA): Ranking, HASC CITI; also NSCEB Commissioner. Silicon Valley defense-tech bridge.
• Rep. Brett Guthrie (R-KY): Chair, House Energy & Commerce. Convened Dec 17 2025 O&I "AI × Biosecurity" hearing.
• Rep. John Joyce, M.D. (R-PA): Chair, E&C O&I. Led Dec 17 hearing. Physician.
• Annabelle Huffman: Staff, E&C O&I. POC for Dec 17 hearing. Annabelle.Huffman@mail.house.gov. High-yield first contact.
• Rep. Yvette Clarke (D-NY): Ranking, E&C O&I. NY-based , proximate to Valthos.
• Rep. Morgan Griffith (R-VA-09): Chair, E&C Health Subcommittee (since July 2025). Writes PAHPA reauth on House side.
• Rep. Frank Pallone (D-NJ): Ranking, E&C. Longtime BARDA champion.
• Rep. Rick Crawford (R-AR): Chair, HPSCI.
• Jonah Shumate: Deputy Staff Director, HPSCI (Jan 2025). Crawford's long-time CoS.
• Rep. Jim Himes (D-CT): Ranking, HPSCI.

6.5 Members of interest (whose offices to know)

• Sen. Todd Young (R-IN): Chair, NSCEB. Bipartisan biotech caucus. Co-led Endless Frontier Act.
  • John Patrick Connell , Chief of Staff.
  • Greg Warren , Legislative Director (2026–).
  • Lauren Burke O'Brien , prior LD.
• Sen. Bill Cassidy (R-LA): Chair, HELP. PAHPA reauth jurisdiction. Physician.
• Sen. Bernie Sanders (I-VT): Ranking, HELP.
• Sen. Alex Padilla (D-CA): NSCEB Commissioner.
• Sen. Marco Rubio (R-FL): bio/national security [verify committee assignments].

7. Commissions, think tanks, industry associations

7.1 Commissions

NSCEB (National Security Commission on Emerging Biotechnology)

• Chair: Sen. Todd Young.
• Vice Chair: Dr. Michelle Rozo (also IQT VP , see §4.2).
• Commissioners: Sen. Alex Padilla, Rep. Stephanie Bice (R-OK), Rep. Ro Khanna, Paul Arcangeli (former HASC SD), Dr. Angela Belcher (MIT), Dawn Meyerriecks (ex-CIA), Dr. Eric Schmidt, Dr. Alexander Titus, Dr. Dov Zakheim.
• Executive Director: Caitlin Frazer. Coordinates 40+ NSCEB staff/fellow team. Central convening node.

Bipartisan Commission on Biodefense (moved to Atlantic Council 2025)

• Co-Chairs: Gov. Tom Ridge (R), Sec. Donna Shalala (D) (since Sen. Lieberman's death March 2024).
• Commissioners: Sen. Tom Daschle, Fred Upton, Anna Eshoo, Susan Brooks, Jim Greenwood, Ken Wainstein, Dr. Margaret Hamburg.
• Executive Director: Dr. Asha M. George, DrPH. Most senior staff in private-sector biodefense advocacy. Wrote "Battle Rattle" (May 2025).
• Deputy ED: Ambika Bumb, PhD.
• Policy Principal: Robert H. Bradley.

7.2 Think tanks & influence organizations

NTI | bio (Nuclear Threat Initiative)

• Jaime Yassif, Ph.D.: VP, Global Biological Policy & Programs. Ex-Open Phil ($40M biosec architect); ex-DoD S&T policy; ex-HHS GHSA. The most networked bio-policy operator in DC.
• Hayley Severance: Deputy VP, NTI | bio.

Johns Hopkins Center for Health Security

• Tom Inglesby, M.D.: Director. Single most-cited US bio expert on the Hill.
• Anita Cicero, J.D.: Deputy Director.
• Faculty: Amesh Adalja, Caitlin Rivers, Gigi Gronvall (DNA synthesis screening , relevant).

Council on Strategic Risks / Janne E. Nolan Center

• Christine Parthemore: Director, Nolan Center. Ex-Sr Advisor to ASD-NCB.
• Hon. Andrew Weber: Sr Fellow. Former ASD-NCB. Also strategic advisor to Ginkgo , relevant for the Ginkgo compete-or-partner question.
• Yong-Bee Lim [verify current title].

SecureBio

• Co-founder: Kevin Esvelt (MIT Media Lab; stepped back from board Sept 2024).
• Executive Director & Board Chair: Dr. Benjamin Mueller (formerly COO).

Blueprint Biosecurity

• Executive Director: Dr. Jake Swett (Oxford DPhil).
• COO: Siobhan Brenton.
• Director of Government Affairs: Sabah Ghulamali. Most relevant first contact.
• Program directors: Brian Renda (Project AIR), Richard Williamson (Far-UVC).

IBBIS (International Biosecurity & Biosafety Initiative for Science)

• Executive Director: Dr. Piers Millett (Geneva HQ).
• Chair: Dr. James Diggans (Twist VP , see §9).

RAND

• Greg McKelvey, Jr.: author of "AI Could Pose Pandemic-Scale Biosecurity Risks."
• Roger Brent: author of "Contemporary Foundation AI Models Increase Biological Weapons Risk."
• David Luckey: lead author DHS-CWMD AI-CBRN study (RR-A2990-1, Jan 2025).

CSIS Global Health Policy Center

• J. Stephen Morrison: SVP & Director.
• Michaela Simoneau: Associate Fellow, biodefense lead.
• Paul Friedrichs, M.D.: former NSC OPPR director, now CSIS.
• Stephanie Psaki: Sr Adviser (non-resident); ex-NSC Coordinator for Global Health Security (Biden era).

Atlantic Council , Forward Defense (Scowcroft Center)

• Joe Costa: Director (since 2025). Ex-DoD DASD-Plans & Posture.

Open Philanthropy / Coefficient Giving

• Andrew Snyder-Beattie, DPhil: Managing Director, Biosecurity & Pandemic Preparedness Fund. Directs $200M+ in grants (rebranded "Coefficient Giving" post-2024 restructure). Field's gatekeeper for non-government talent flow.

Convergent Research

• Adam Marblestone: CEO & Co-Founder. Well-networked across NSCEB, DARPA, BARDA.

Helena

• Henry Elkus: Founder & CEO. Runs "Biosecurity in the Age of AI" project (Bellagio Summit 2023).

FAS (Federation of American Scientists)

• Daniel Correa: CEO.
• Dr. Jedidah Isler: Chief Science Officer (Jan 2025). Ex-OSTP Principal Assistant Director.

7.3 Industry associations

BIO (Biotechnology Innovation Organization)

• John F. Crowley: President & CEO. Combat veteran & former Naval Intelligence officer with JSOC. Biosecurity is one of his 7 strategic tenets.
• Phyllis Arthur: SVP, Healthcare Policies & Programs.
• Aiken Hackett: SVP, Federal Government Affairs.

APHL (Association of Public Health Laboratories)

• Scott Becker: CEO since 1997. Co-founded LRN with CDC/FBI. APHL = channel to every state PHL. Indirect channel access worth >$5M lifetime. LinkedIn: linkedin.com/in/scott-becker-399064a.
• Dr. Timothy Southern: Chair, APHL Biosafety & Biosecurity Committee (Nevada State PHL).

IGSC (International Gene Synthesis Consortium)

• Chair/President: Dr. James Diggans , VP Policy & Biosecurity, Twist Bioscience. See §9.

8. Commercial: AI labs

8.1 OpenAI

• Dylan Scandrett: Head of Preparedness (appointed Feb 2026 by Altman). Newly empowered with bio/CBRN risk-mitigation budget. Valthos's red-team/eval product is exactly what his org sources.
  • Deal size: $2–10M ARR (eval contracts + mitigations).
  • Contact: cold via X/LinkedIn; warm via Jason Kwon.
• Jason Kwon: CSO. Already on Valthos record. Champion / economic buyer.
• Aleksander Madry: former Preparedness lead, now in safety org [verify current title]. Influencer.

8.2 Anthropic

• Logan Graham: Head of Frontier Red Team. Built and runs Anthropic's bio red-team (virology evals, constitutional classifiers, capability thresholds). House testimony Dec 17 2025. LinkedIn: logangraham. Top commercial AI-lab contact.
  • Deal size: $1–5M ARR pilot.
  • Channels: Yale Law Frontier AI Colloquium, DEF CON, Rhodes Scholar network.
• Jack Clark: Co-founder & Head of Policy. Owns RSP narrative and external-partnership posture. Public statements on "powerful systems by late 2026/early 2027."

8.3 Google DeepMind

• Four Flynn / Helen King / Anca Dragan: co-authors, Frontier Safety Framework v3 (Sept 2025). Codifies CBRN as tracked critical capability level.
• Ashley Otter, Ph.D.: Virology/Microbiology SME, ReDI team (Responsible Development & Innovation , AlphaFold-3 biosec review team). Ex-UKHSA Rare and Imported Pathogens Lab. Best individual technical contact at DeepMind for a bio-evals partnership. LinkedIn: linkedin.com/in/ashley-otter-32aa2270.

8.4 NVIDIA / BioNeMo

• Kimberly Powell: VP, Healthcare, NVIDIA. Owns BioNeMo P&L + Lilly co-innovation lab + Thermo Fisher autonomy partnership. Strategic partner / co-marketing angle: Valthos as safety/biosecurity layer for BioNeMo-hosted models.
  • Deal size: $5M+ strategic.
  • Channels: J.P. Morgan Healthcare Conference, NVIDIA GTC, Jensen's bio summits.

8.5 Microsoft / Meta / xAI / Hugging Face

• Eric Horvitz: Microsoft Chief Scientific Officer (named on IDT/Microsoft AI screening partnership). Likely champion for AI-bio screening partnerships at Microsoft.
• Meta, xAI, Hugging Face , public bio-safety leads thin [unverified].

9. Commercial: DNA synthesis providers

• James Diggans, Ph.D.: VP Policy & Biosecurity, Twist Bioscience + Chair of IGSC. Promoted to VP April 2025. Single most important node in the synthesis-screening ecosystem. Win Diggans = win IGSC consensus across all members.
  • Deal size: $500K–$2M ARR (screening AI tooling) + halo across IGSC.
  • Channels: IGSC meetings, ABSA conferences, SynBioBeta, direct via IBBIS.
  • LinkedIn: linkedin.com/in/jdiggans.
• Demaris Mills: President, Integrated DNA Technologies (Danaher). IDT has publicly committed to AI screening partnerships (Microsoft is named , door is open).
  • Deal size: $500K–$2M.
  • Channels: Danaher Life Sciences ops, warm intros via IGSC.
• Ray Chen, Ph.D.: President, GenScript Life Science Group (USA). Under BIOSECURE Act overhang, GenScript USA has political incentive to demonstrate gold-standard screening , US-built AI tool politically valuable. LinkedIn: linkedin.com/in/rchen10001.
• Kening Li: General Counsel & CCO, GenScript. Compliance/regulatory dimension.
• Eurofins / Ansa / Telesis / Thermo Fisher: [unverified named contacts]. Route via IGSC member roster.

10. Commercial: Pharma / large biotech

• Deborah Donovan: SVP, Head of EHS, Moderna. Since Jan 2022; prior SVP EHS at Takeda + Global Head EHS at Novartis (3x repeat buyer). LinkedIn: linkedin.com/in/deborah-donovan-4449b819.
  • Deal size: $250-750K ARR; $2-5M multi-site.
  • Channels: ISPE, ABSA, LinkedIn (Boston).
• José M. Vega, M.D.: Chief Safety Officer, Moderna. Tangential influencer.
• Louise Proud: VP, Global EHS, Pfizer. 25+ year tenure; single budget owner for any biosafety-AI sale at Pfizer.
• Lev Kubiak: VP & Chief Security Officer, Pfizer. Ex-DHS HSI Assistant Director International Ops. Instantly understands national-security framing. Best route in for Valthos's defense narrative at Pfizer.
• B. Adam Williams: Sr Director, Pandemic Preparedness Commercial Lead, Pfizer. Direct JTBD overlap.
• Regeneron / BioNTech / Vertex / Merck / GSK / Sanofi / Roche-Genentech / AstraZeneca / Novartis / Lilly / J&J / AbbVie / Amgen / Gilead / Takeda / BMS: specific named EHS / biosecurity heads [unverified , route via ISPE EHS COP directory, ABSA International member roster, LinkedIn "Head of Biosafety" by company].

11. Commercial: CROs, cloud labs, Ginkgo

• Matt McKnight: Founder & CEO, Perimeter (spun out from Ginkgo Bioworks April 2026; $60M growth capital). Inherited the bulk of Ginkgo Biosecurity's operating assets and customer relationships (IARPA FELIX/ENDAR, CDC traveler-based genomic surveillance, APHL distribution, EU + military treatment facility contracts). JE-RDAP IDIQ prime status novation to Perimeter is not publicly confirmed. The dominant infrastructure-heavy competitor regardless. Track, do not pursue.
  • The compete-or-partner question lives here.
  • Channels: direct warm via Palantir alumni; Ferment conference; HBS network.
• Andy Weber: Strategic Advisor, Ginkgo. Also CSR Sr Fellow. Cross-cover.
• Charles River / Labcorp / IQVIA / Emerald Cloud Lab / Strateos / Synthego: [unverified named contacts]. Default channels: ABSA, AAALAC.

12. Commercial: insurance & reinsurance

• Dr. Gunther Kraut: Global Head of Epidemic Risk Solutions, Munich Re. Built ERS in 2017; launched The Pandemic Consortium at Lloyd's Feb 2026 (parametric pandemic insurance). Valthos's biosurveillance + pathogen-forecast data is direct underwriting input.
  • Deal size: $1-3M ARR data/risk-model license; consortium-scale if syndicated.
  • Channels: London/Munich/Singapore offices; Lloyd's market events; Monte Carlo Rendez-Vous (Sept); Pandemic Consortium partner network.
• Paul Murray: CEO Life & Health Reinsurance, Swiss Re. Public author of continued-excess-mortality thesis.
• Bernhard Kaufmann: Group CRO, Swiss Re (effective Oct 2025).
• Hannover Re / SCOR / Marsh / Aon / Beazley / Hiscox / MS Amlin: [unverified named contacts]. Route via Pandemic Consortium membership (likely public Q3 2026).

13. Commercial: defense primes & FFRDCs

13.1 Defense primes

• Tim Reardon: President, Defense & Intelligence business, Leidos [verify currency]. Leidos won the $4B DTRA CWMD IDIQ May 2024 (Pool 1: AI/ML for CBRN , natural Valthos sub-vehicle).
  • Deal size: $5-25M task orders.
  • Channels: NDIA CBRN Division; DTRA industry days.
• BG (Ret.) William King: Principal & Senior Fellow, Booz Allen (CWMD market lead). Former Commanding General, 20th CBRNE Command. Chair, NDIA CBRN Division. Single highest-leverage non-government door-opener into DoD CBRN.
  • Channels: NDIA CBRN Quarterly Forum (he chairs); LinkedIn; CBRNe Society events.
• Nicole Funk: SVP, Booz Allen (CBRNE practice). Named lead on JE RDAP $8.27B IDIQ.
• SAIC, CACI, BAE, GD-IT, Noblis, Peraton, ManTech: [unverified named bio BD contacts]. Route via NDIA CBRN Division roster.

13.2 FFRDCs / labs / UARCs

• Dr. Monique Mansoura: Executive Director, Global Health Security & Biotechnology, MITRE. Public-facing biosec/biopreparedness lead; runs policy translation between DoD/HHS and industry. Strong convening power.
  • Channels: BIO International, Aspen Security Forum.
• Dr. Benjamin L. Ervin: Leader, Counter-WMD Systems Group, MIT Lincoln Laboratory. Runs CBRN sensing, ML, red-teaming group. Co-leads: Dr. Diane C. Jamrog, Dr. Brian C. Lee, Dr. Kevin M. Tangen.
• Dr. Barry Grabow: Mission Area Executive, Global Health, JHU APL. Biothreat surveillance + CBRNE programs.
• Joe Behling: PM, Counter CBRNE Threats Program Area, JHU APL.
• Dr. George W. Korch, Jr.: NBACC Director (BNBI) [appointed 2018; verify currency]. NBACC PIs: Ty Sornberger, Ashley Kondas, Hank Askin, Adam Bazinet. NBACC is GOCO/FFRDC , credibility validator, not direct buyer.

14. Commercial: agriculture, food, critical infra, hospitals, VC referral

14.1 Agriculture / food (H5N1 + ASF exposure)

• Dr. Bill Hewat, DVM: MD Veterinary Services, Tyson Foods. Direct ownership of biosecurity protocols during ongoing H5N1 crisis. LinkedIn: linkedin.com/in/bill-hewat-4a4a4b44.
  • Deal size: $250K-$1M ARR.
  • Channels: AAAP, AVMA, Arkansas Livestock & Poultry Commission.
• Scott Gustin, DVM: MD Vet Services, Tyson [verify ranking vs Hewat].
• Sean Leighton: VP, Food Safety, Quality & Regulatory Affairs, Cargill.
• Maria Wedel: VP, Food Safety, Quality & Regulatory Affairs, Cargill.
• JBS / Smithfield / Perdue / Bayer Crop / Corteva / Syngenta / ADM / DFA: [unverified named contacts]. Default: AAAP, USAHA Foreign Animal Disease Committee.

14.2 Critical infrastructure / wastewater

• Dr. Mariana Matus: CEO & Cofounder, Biobot Analytics. Original CDC NWSS contractor (lost to Verily); won ONDCP nationwide wastewater contract Jan 2026. Already partnered with Twist, Ginkgo, Illumina, Broad. Best individual contact in wastewater-biosurveillance for a strategic co-sell.
  • Channels: MIT alum network, Cambridge biotech.
• Newsha Ghaeli: President & Cofounder, Biobot.
• Verily Life Sciences: wastewater program lead [unverified specific PM]. Holds current $41M CDC NWSS contract (#75D30124C18440).
• WastewaterSCAN: academic-side: Marlene Wolfe (Emory), Alexandria Boehm (Stanford).
• American Water / Veolia NA / NYC DEP / CBP OFO / PANYNJ: [unverified named contacts].

14.3 Hospital systems & PHLs

• Scott Becker: CEO, APHL (see §7.3). The channel to every state PHL.
• Dr. Timothy Southern: Chair, APHL Biosafety & Biosecurity Committee.
• HCA, Kaiser, Cleveland Clinic, Mayo, MGB, NYC H+H , [unverified named infection-control leads]. Default: APIC directory.

14.4 Academic partners for STTR / R01 / co-PI structures

• Dr. Andy Kilianski: CSTO, UCSF Quantitative Biosciences Institute (QBI). Just transitioned from ARPA-H HSF (~May 2026). QBI builds deep PPI maps; Valthos's PLM stack predicts PPI dynamics. The clearest single academic partnership fit nationwide. Use for: (a) STTR-required academic co-PI, (b) NIH R01 partner for mechanistic protein work feeding Valthos's platform, (c) translation/product-development advisor, (d) referrer to ARPA-H Mission Offices and HHS-side academic networks.
• Broad Institute: sequencing + biothreat surveillance partnerships (already in Biobot's network).
• MIT Media Lab / SecureBio (Kevin Esvelt): adjacent biosec partnership.
• Johns Hopkins APL + Columbia / Mount Sinai / NYU virology: East Coast academic partners for R01-led mechanistic work.
• Stanford / Emory (WastewaterSCAN , Marlene Wolfe, Alexandria Boehm): wastewater epi academic anchors.

14.5 Biotech VC referral channel

• Dr. Raj Panjabi: Senior Partner, Flagship Pioneering (Preemptive Health & Medicine Initiative). Former White House NSC top pandemic official under Biden , executed the 2022 National Biodefense Strategy. Sits on Bipartisan Commission on Biodefense. Single highest-leverage biotech-VC introduction node for a biodefense startup.
  • Channels: Bipartisan Commission events; Harvard Med faculty network.
• Craig Williams: CEO Operating Partner, Flagship. Currently building Apriori (variant-proof vaccines/antibodies). direct adjacent JTBD.
• Amanda Kay: Senior Partner & Chief BD Officer, Flagship.
• a16z Bio + Health: Jorge Conde, Vineeta Agarwala, Julie Yoo (GPs); Vijay Pande (former GP). $750M+ Bio Fund III. Pande + Conde host Raising Health podcast.
  • Channels: a16z Bio Summit (Nov); podcast pitch; Stanford/Harvard.
• ARCH / GV / Section 32 / 8VC / Khosla Bio: Bob Nelsen (ARCH), Krishna Yeshwant (GV) are publicly biodefense-tilted partners.

15. Outreach sequencing & warm-intro paths

15.1 First-30-day call list (named individuals, by category)

15.2 Highest-leverage warm-intro chains

0. The Kilianski / UCSF QBI chain (new May 2026): Andy Kilianski just transitioned from ARPA-H HSF to CSTO, UCSF QBI. He is SF-local, deeply networked across ARPA-H + NIAID + DoD biothreat, and publicly recruiting new ARPA-H PMs. Three plays in one relationship: (a) academic co-PI for STTR / R01 / NIAID Omnibus BAA RA002; (b) referrer into ARPA-H Tyler Best + the new biothreat PM successor; (c) source a Valthos-aligned ARPA-H PM candidate (high-leverage long game).

1. The Palantir alumni chain (Valthos's strongest internal asset , McMahon ran Palantir Life Sciences 7 yrs):

   • Palantir alum → James Diggans (Twist VP Policy & Biosec / Chair of IGSC) → state PHL channel via Scott Becker (APHL). Note: the previously identified McKnight intro is broken; he runs Perimeter (Valthos's competitor) as of April 2026.

2. The Lux Capital chain (Tess van Stekelenburg is sitting Lux Partner):

   • Lux portfolio → Anduril/Saildrone alumni → DoD CBRN BD primes → BG (Ret) King at Booz Allen + NDIA CBRN Division.

3. The OpenAI chain (already on cap table):

   • Jason Kwon → Dylan Scandrett (Preparedness) → cross-lab to Logan Graham (Anthropic Frontier Red Team) → DeepMind ReDI (Ashley Otter).

4. The NSCEB / IQT chain:

   • Michelle Rozo sits at both IQT B.Next (with Tara O'Toole + Kevin O'Connell) AND NSCEB Vice Chair under Sen. Todd Young. Single relationship unlocks both IC strategic-investor channel and NSCEB policy-recommendation network.

5. The ASD ND-CBD chain:

   • Dr. Robert Kadlec is a famous biodefense hawk with deep BARDA + OWS roots. Warm intro via JHU CHS (Inglesby was his peer) or NTI (Yassif) or via the Bipartisan Commission (Asha George). Once warm: Kadlec opens DTRA Petro, JPEO Goodwin, BARDA Disbrow simultaneously.

6. The "Biodefense Czar" chain:

   • Gerald Parker is reachable via Texas A&M Bush School network, via Bipartisan Commission on Biodefense (he previously sat on related advisory bodies), or via his USAMRIID command alumni.

15.3 Conference / event strategy

15.4 Acquisition-vehicle first moves

1. DTRA: respond to FY25-2034 Chem-Bio Fundamental Research BAA (HDTRA1-25-S-0001); next deadline 2 March 2026 for Topics B1-B6. Email white paper to FRBAA mailbox.
2. JPEO: pursue MCDC RPP through ATI (already a member). Target JPL EB (Goodwin) and JPM CBRN Medical (Nuckols).
3. DARPA BTO: white paper to Anne Cheever via ice@darpa.mil; track BTO Office-Wide BAA HR001120S0019.
4. DIU: pitch via Whitchurch's Human Systems portfolio against an open Area of Interest on diu.mil/work-with-us.
5. ARPA-H: Mission Office ISO Solution Summary submitted to HSF with Kilianski as the target PM.
6. BARDA: TechWatch quad chart via TechWatchInbox@hhs.gov targeting CBRN MCMs (Houchens) and IEID (Armstrong); in parallel DRIVe EZ-BAA through Subedee.
7. IARPA: respond to B24IC successor announcements; Patterson is the PM.
8. In-Q-Tel: pitch B.Next via O'Connell + O'Toole + Rozo.

16. Sources of error & honest caveats

• Contracting officer names are mostly NOT public. SAM.gov shows mailboxes (e.g., DTRA FRBAA mailbox), not individual COs. Plan to identify the CO on each specific solicitation rather than chasing them up front.
• Political appointee churn is high in Trump II. Several seats above are vacant, acting, or pending Senate confirmation: ASPR Asst Sec (vacant), NIAID Director (vacated by Marrazzo Jan 2026), CDC Director (Schwartz pending), OUSD R&E bio principal director (unverified). Anchor outreach on career SES below the political layer , they don't churn:
  • Disbrow (BARDA), Erbelding (NIAID DMID), Houchens (BARDA CBRN), Walke (CDC ORR), Adams (SNS), Joyner (ASPR Industrial Base), Benford (BARDA CMA), Mair (FDA MCMi), Petro (DTRA RD), Kless (DTRA Acq), Pope (DTRA CTR), Goodwin (JPL EB), Whitchurch (DIU Human Systems), Kilianski (ARPA-H HSF).
• Several specific roles flagged [unverified] in this map:
  • USAMRIID Director of Science; USAMRIID Virology Division Chief.
  • DTRA RD-CB Department Director (Hann elevated; successor not publicly posted).
  • Robert Saperstein deputy role at DARPA BTO.
  • OUSD R&E bio principal director.
  • OSTP biosecurity / dual-use policy lead (specific named individual).
  • OMB PAD-H (specific named individual).
  • NCMI Director.
  • NCBC Director (ODNI).
  • HAC-LHHS current chair confirmation.
  • Pharma EHS/biosec leads beyond Moderna and Pfizer.
  • Most named contacts at non-Tyson/non-Cargill ag/protein companies.
  • Verily wastewater program PM.
• Recommend a follow-up phase via: direct LinkedIn outreach for company-specific roles; public affairs offices (USAMRIID PA Caree Vander Linden, DTRA PA Ms. Melissa Tune, DARPA PA) for verification of acting/transitional government roles; LegiStorm Pro pulls for Hill staff with email + phone.
• Cross-references with main brief: this persona map should be read alongside the market primer. The deep-dive provides programs, budgets, and frameworks that contextualize each persona's authority.

End of persona map. ~6,000 words. Last verified 2026-05-11.